Introduction
The human myeloid leukemia cell line HL-60 provides an interesting model for studies on the control of cell growth and differentiation. 1 Previous in vitro studies have shown that alltrans retinoic acid (RA), a vitamin A derivative, induces morphologic changes consistent with terminal maturation of HL-60 cells into mature granulocytes. [2] [3] [4] RA has been successfully used to induce remission of a majority of patients with acute promyelocytic leukemia, 5, 6 but its mechanism of action is unknown. RA modulates the expression of many gene products including cytokines, 7 components of the hemostatic system [8] [9] [10] [11] and cell surface adhesion molecules. 12, 13 These latter mediate interaction of hematopoietic cells with extracellular matrix proteins present in their local microenvironment and are likely to play a critical role in the regulation of cell proliferation/differentiation. 14, 15 Recently, it has been recognized that adhesion receptors, like cytokines receptors, can directly transmit signals into cells. 16 In bone marrow, the extracellular matrix (ECM) is made of several components including collagens, hemonectin, fib- ronectin, tenascin, laminin, thrombospondin and glycosaminoglycans, some of which have been shown to promote myeloid maturation. 17, 18 Thrombospondin-1 (TSP) is a large trimeric disulfide-linked glycoprotein (M r 450 000) with functional domains capable of binding calcium, heparin, collagens and other matrix components, and cell surface receptors including CD36, heparan sulfate proteoglycans and integrins. 19 TSP is synthesized, secreted in the culture medium, and incorporated into the ECM of a variety of normal and tumor cells. 20 It has been reported to induce attachment, spreading, motility and growth of different cell types. 21 However, depending on the repertoire of cell receptor expression and local ECM context, TSP may induce only attachment or attachment and spreading; 21 it may also exert opposite effects on cell proliferation. 22, 23 TSP is present in the ECM associated with active hematopoiesis and serves as an adhesive ligand for pluripotent as well as committed progenitor cells of each lineage. 24, 25 The cell binding domain resides toward the Cterminus of the molecule 24 whereas the N-terminus has potential growth regulatory effect. 26 The ability of cells to attach to TSP is lost in mature erythroid cells and only a fraction of mature granulocytes retain this capacity. 24 Yet, TSP has many effects on polymorphonuclear leukocytes as it promotes motility and degranulation, and enhances phagocytosis and oxidant generation in these cells. 27 Recently, it was shown that TSP receptors on neutrophils are associated with G-proteins, suggesting a potential role for TSP in cell signaling. 28 Undifferentiated HL-60 cells acquire the ability to adhere and migrate in response to TSP upon differentiation toward neutrophils by dimethyl sulfoxide. 27, 29 HL-60 is the most widely used of the human myeloid leukemia cell lines for studying differentiation as it may be induced to differentiate in vitro to either neutrophils or monocytes depending on the agent used. 1 In addition, HL-60 cells can proliferate in serumfree nutrient medium which allows the dosage of secreted constituents which are normally present in serum. Recent studies have shown that TSP is upregulated during RAinduced differentiation of neuroblastoma and embryonal carcinoma cells to neurons. 30, 31 In this study we investigated TSP production by HL-60 cells during their differentiation into monocytes by phorbol esters or granulocytes by RA. We demonstrate that TSP has an autocrine role in the growth regulation and differentiation of HL-60 cells in response to stimulation with RA.
Materials and methods

Reagents
The phorbol ester phorbol-13-monoacetate (PMA) and alltrans retinoic acid (RA) were from Sigma Aldrich Chimie (St Quentin Fallavier, France); they were dissolved in DMSO and ethanol, respectively, as 2 × 10 −3 M and 10 −4 M stock solutions, and diluted in RPMI before each experiment. Thrombospondin-1 (TSP) was purified from the supernatant of thrombinactivated human platelets, as described previously. 32 The purity of this preparation was assessed by high performance liquid chromatography, electrophoresis on SDS-polyacrylamide gel and immunoblotting. The purified protein gave a single band (M r 180 000) on electrophoresis in the presence of SDS and ␤-mercaptoethanol. Anti-TSP antibodies, used in this study as purified IgGs, were the rat monoclonal antibody 5G11 prepared in our laboratory 33 and the polyclonal antibodies R1 and R5, a kind gift of Pr J Lawler (Harvard Medical School, Boston, MA, USA). The specificity of these antibodies has been previously demonstrated by immunoblotting using platelet lysates. 33, 34 The R5 antibody, which has been prepared against a fusion protein encompassing residues 784-932 of human TSP-1, inhibits platelet aggregation. 34 The R1 antibody has been used to immunolocalize TSP in MCF-7 cells and HUVEC. 35 A pan-specific TGF-␤ polyclonal IgG, neutralizing isoforms 1, 2, 3 and 5, and recombinant human TGF-␤1 were from R and D Systems Europe (Oxon, UK). All reagents for cell cultures were from GIBCO BRL, Life Technologies (Cergy-Pontoise, France).
Cell culture and differentiation assay
The HL-60 acute human myeloid leukemia cell line was obtained from ATCC (Rockville, MD, USA). Cells were maintained in suspension culture at 3.5 × 10 5 cells/ml in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin G and 100 g/ml streptomycin, at 37°C with 5% CO 2 . Media were replaced every 2-3 days. At the beginning of each experiment, cells were washed three times with serum-free RPMI and seeded at 3.5 × 10 5 /ml in 24-well culture dishes (Costar, Cambridge, MA, USA), in a defined medium consisting of RPMI 1640 supplemented with 1 mg/ml bovine serum albumin (BSA), 5 g/ml human transferrin and 5 g/ml bovine insulin. Cells were induced to differentiate into macrophages with 4 × 10 −8 M PMA or granulocytes with 10 −7 M RA. For the untreated controls, the same final amount of DMSO or ethanol was added in the culture medium.
TSP levels in culture medium and cell lysate Cells (3.5 × 10 5 /ml) were incubated with PMA or RA for the time indicated. Culture supernatants were harvested after centrifugation of the cells and cells were washed with RPMI and counted. They were lysed with phosphate-buffered saline (PBS) containing 0.1 M NH 4 OH, 0.1% Triton X-100, 1 mM phenyl-methyl-sulfonyl-fluoride and 10 mM N-ethyl-maleimide as described. 36 Both the culture media and cell extracts were clarified by low speed centrifugation and stored at −80°C until the assay. TSP was quantified by enzyme-linked immunosorbent assay (ELISA), using the rat monoclonal antibody 5G11 and the polyclonal antibody R1, as reported before. 36 Purified TSP used as a standard was diluted in the appropriate medium. Each assay was done in triplicate and the mean of three independent experiments ± s.d. was calculated.
Cell proliferation and differentiation
Cell proliferation was evaluated by direct cell counting (trypan blue dye exclusion method) using a hemocytometer chamber.
Cell differentiation was quantified by the nitroblue tetrazolium (NBT) dye reduction assay. 2 Cells containing blue black diformazan deposits visible on Wright-Giemsa-stained cytospin slides were counted (at least 200 cells per experimental condition) and the percentage of positive cells was calculated.
Assessment of the role of TSP in cell proliferation and differentiation HL-60 cells were treated with 10 −7 M RA on day 0 and 25 g/ml of either a polyclonal anti-TSP antibody, R1 or R5, or an anti-TGF-␤ antibody, or a rabbit nonimmune IgG, were added on days 0 and 1. Cells incubated in a 5% CO 2 atmosphere at 37°C were counted and examined for differentiation at the indicated times. In another set of experiments, HL-60 cells were grown in the presence of purified TSP (0.1-5 g/ml) or TGF-␤ (2.5 ng/ml). In selected samples, TSP (1.5 g/ml) was preincubated for 30 min with the polyclonal antibody R5 (25 g/ml) before being added to HL-60 cells.
Statistical analysis
The results are presented as the mean ± s.d. of data obtained from at least three experiments performed in triplicate. Significance of differences between parameters measured for untreated and treated cells was estimated with the Student's t-test for paired samples.
Results
Quantitation of TSP levels in HL-60 cell culture
Because TSP is present at high concentration (Ϸ20 g/ml) in FCS and crossreacts with our antibodies in the ELISA, these experiments had to be performed in serum-free medium. HL-60 cells could be maintained for up to 5 days in RPMI medium supplemented with 1 mg/ml BSA, 5 g/ml human transferrin and 5 g/ml bovine insulin, with more than 90% viable cells. Under basal conditions, HL-60 cells secreted an approximate 13.5 ± 6.0 ng/10 6 cells/24 h. Only traces of the protein (Ͻ5 ng/10 6 cells) were measured in cell lysates indicating that the protein was constitutively secreted into the medium. PMA used at 4 × 10 −8 M, a dose that induced the adhesion of 72% of HL-60 cells at 24 h, did not change the level of TSP secreted by HL-60 cells (Figure 1 ). PMA was not studied for longer times as we observed a high percentage of non-viable cells after 2 days of PMA exposure. In contrast, RA used at 10 −7 M induced a marked increase in TSP secreted by HL-60 cells. The effect was observed after 1 day of RA exposure ( Figure 2 ) and lasted up to 5 days of culture reaching a value of 900 ng/10 6 cells (mean of two experiments). In these experiments, the intracellular levels of TSP remained very low indicating that the bulk of synthesized TSP was secreted into the culture medium.
Effects of anti-TSP antibodies on growth of RA-treated HL-60 cells Treatment of HL-60 cells with 10 −7 M RA resulted in a rapid decrease in proliferation under our conditions, ie in the absence of serum. A significant difference in cell number was observed between control and RA-treated cultures by day 1 of RA exposure (Figure 3 ). To examine whether the antiproliferative effect observed in RA-treated cells was TSPdependent, a polyclonal anti-TSP IgG (25 g/ml), either R1 or R5, was added to RA-treated cultures on days 0 and 1. Addition of R1 partially counteracted the effect of RA on HL-60 growth whereas addition of R5 maintained the growth of RA-treated HL-60 cells at control levels up to 3 days, demonstrating that the effect of RA on cell proliferation may be mediated by TSP generated by the cells (Figure 3 ). Further addition of R5 (25 g/ml) at day 3 of culture did not result in a supplementary inhibitory effect at day 5. Control nonimmune IgG did not affect the growth of RA-treated HL-60 cells (same curve as RA on the Figure) . Because TSP has been shown to have the ability to activate latent TGF-␤ in cell cul-
Figure 3
Effects of anti-TSP or anti-TGF-␤ antibodies on proliferation of RA-treated HL-60 cells. HL-60 cells were incubated in serumfree defined medium in the absence or presence of 10 −7 M RA. Anti-TSP IgG, either R1 or R5, or anti-TGF-␤ IgG were added at 25 g/ml to RA-containing cultures on days 0 and 1. Cells were counted using a hemacytometer chamber after 1, 3, and 5 days. Each point represents the mean value ± s.d. of three experiments. Cell viability, determined as described in Materials and methods, was Ͼ90%.
tures, 37, 38 we tested whether the anti-proliferative effect of TSP on HL-60 cells might be TGF-␤-mediated. In fact, addition of neutralizing anti-TGF-␤ IgG to the cell cultures (25 g/ml) did not affect the growth of RA-treated HL-60 cells (Figure 3 ).
Effects of anti-TSP antibodies on differentiation of RAtreated HL-60 cells
Differentiation of HL-60 cells into granulocytes results in morphologic changes and NBT positivity. Under serum-free conditions, NBT positivity was detected in about 19, 27 and 44% of cells after 1, 3 and 5 days of treatment, respectively (Table 1) . To assess the contribution of TSP to these RAinduced events, anti-TSP IgGs (25 g/ml) were used to block TSP function during cell differentiation. The percentage of differentiated HL-60 cells treated with RA in the presence of the RA on day 0 when they were plated in RPMI 0.1% BSA containing 5 g/ml of insulin and transferrin. Anti-TSP IgG (25 g/ml), R1 or R5, or anti-TGF-␤ IgG (25 g/ml) were added to RA-treated cultures on days 0 and 1. Granulocytic differentiation was assessed by the NBT reduction assay. Data (mean ± s.d.) presented were from three experiments performed in triplicate.
anti-TSP IgG R5 was significantly reduced at any time considered (31 ± 1 vs 44 ± 1 at day 5), demonstrating a role for TSP in HL-60 cell differentiation ( Table 1) . The antibody R1 which was less efficient than R5 in inhibiting cell proliferation (Figure 3 ) was also less efficient in inhibiting cell differentiation. Control nonimmune IgG (not shown) or anti-TGF-␤ IgG (25 g/ml) did not affect the differentiation of RA-treated HL-60 cells. Thus, these results strongly suggested that TSP promoted the differentiation of HL-60 cells.
Effects of purified TSP on growth and differentiation of HL-60 cells
To confirm a role for TSP in the growth and differentiation of HL-60 cells, we examined whether the addition of soluble TSP (0.1-5 g/ml) by itself, in the absence of RA treatment, would inhibit growth and promote differentiation of cells cultured under serum-free conditions. Indeed, a decrease in cell proliferation was noted upon addition of TSP at concentrations Ͼ0.5 g/ml, with complete cessation of growth observed at 1.5 g/ml (Figure 4) . Preincubation of purified TSP (1.5 g/ml) with the anti-TSP antibody R5 (25 g/ml) eliminated the effect of the TSP preparation on cell proliferation, demonstrating that TSP, and not a possible contaminant, was having this effect. The anti-TSP antibody did not have a significant effect on cell proliferation when added alone (not shown). In parallel, soluble TSP at the same concentration (1.5 g/ml) was found to promote markedly the differentiation of HL-60 cells (Table 2) . With 5 g/ml TSP, the number of differentiated cells was even similar to that of RA-treated cells at the two times tested (compare with RA in Table 1 ). Consistent with previous reports, 39,40 addition of 2.5 ng/ml recombinant TGF-␤1 to untreated HL-60 cells did not modulate their growth or differentiation.
Figure 4
Effects of purified TSP or recombinant TGF-␤ on growth of HL-60 cells. HL-60 cells were plated in serum-free defined medium in the presence of increasing concentrations of TSP (0.1-5 g/ml) or TGF-␤ (2.5 ng/ml). In selected experiments, TSP (1.5 g/ml) was preincubated with the polyclonal antibody R5 (25 g/ml) before addition to the cells. Cells were counted using a hemacytometer after 1, 3 and 5 days. Each point represents the mean value ± s.d. of three experiments performed in triplicate. Effect of TSP on the differentiation of HL-60 cells. Cells were plated on day 0 in RPMI 0.1% BSA containing 5 g/ml of insulin and transferrin in the presence of various concentrations of purified TSP as indicated. Granulocytic differentiation was assessed by the NBT reduction assay. Data (mean ± s.d.) presented were from three experiments performed in triplicate.
Discussion
Many types of mammalian cells synthesize and secrete TSP and express receptors for TSP, including monocytes and neutrophils under certain circumstances. [19] [20] [21] [27] [28] [29] Recently, the synthesis of TSP was shown to be induced as an immediateearly response to RA in neuroblastoma and embryonal carcinoma cells, and a functional role for TSP in the early differentiation of these cells was established. 30, 31 Myeloid leukemic cells, such as HL-60 and NB4, differentiate in vitro into granulocyte-like cells in response to RA [2] [3] [4] and RA equally differentiates acute promyelocytic leukemia cells from patients in vitro and in vivo, resulting in cytological and cytogenetic complete remission. 5, 6 In this study, we investigated the potential role of TSP in the growth arrest and/or differentiation of the RA-sensitive HL-60 myeloid leukemic cells. We first determined that HL-60 cells constitutively secreted low amounts of TSP in the culture medium, ie 13 ± 6 ng/10 6 cells/24 h. We were interested to see whether the differentiation of these leukemic cells to either monocytes/ macrophages by PMA or granulocytes by RA would result in changes in TSP secretion. These experiments were conducted under serum-free conditions because TSP present in the serum interferes in the ELISA test. HL-60 cells can proliferate in serum-free nutrient medium (eg RPMI 1640) with more than 90% viable cells provided that it is supplemented with insulin and transferrin. 1 In the absence of serum, the arrest of cell proliferation induced by 4 × 10 −8 M PMA was immediate and Ϸ70% of HL-60 cells became adherent to the culture dish within 24 h of treatment. At this time, we found no induction of TSP secretion by HL-60 cells and the effect of this agent was not studied for a longer time because we observed a cytotoxic effect at 2 days of treatment. In contrast, a strong increase in TSP secretion was measured during the differentiation of HL-60 cells into granulocytes upon RA treatment. An increase in TSP secretion was apparent at 24 h when only 20% of cells were differentiated and the progressive increase over a 5 day period paralleled cell differentiation as measured by the development of NBT positivity. At 5 days, when Ϸ50% of cells were differentiated, a 10-fold increase in the level of TSP was measured in the conditioned medium of HL-60 cells.
We determined the role of TSP in the proliferation and differentiation of RA-treated cells by examining the effect of adding neutralizing TSP antibodies to RA-treated cultures. We found that the addition of a polyclonal anti-TSP antibody to HL-60 cells resulted in immediate neutralization of the antiproliferative effect of RA. Because active TGF-␤ produced in RA-treated HL-60 cultures may exert an anti-proliferative activity on these cells 39, 40 and TSP was shown to activate latent TGF-␤ in cell cultures, 37, 38 we wondered whether the effect of TSP on HL-60 proliferation might be mediated by TGF-␤. However, our results do not support a role for TGF-␤ in the present study. First, under our experimental conditions, we were unable to modulate the proliferation of RA-treated HL-60 cells, using a pan-specific TGF-␤ neutralizing antibody. This is at variance with results published previously by Nunes et al 40 and may relate to the fact that we used a 10-fold lower concentration of RA than those authors. Indeed, treatment of HL-60 cells with 10 −7 M RA, the dose used in this study, was shown to produce less than 0.1 ng/ml active TGF-␤ at 3 days, 39 which is 10 times less than the dose at which TGF-␤ exerts an anti-proliferative effect on RA-treated HL-60 cells. 40 Second, in our study the anti-TSP antibodies exerted a negative effect on both the proliferation and differentiation of HL-60 cells whereas TGF-␤ has no effect on granulocytic differentiation even in those studies where it was shown to exert an anti-proliferative effect. 39, 40 Third, the addition of soluble TSP to untreated HL-60 cells resulted in immediate arrest of cell growth and promotion of cell differentiation, an effect that could not be reproduced by the addition of recombinant active TGF-␤ (Refs 39, 40 and this study). Thus, it is likely that TSP acts on HL-60 cells by a mechanism different from the mechanism of action of TGF-␤. It was shown previously that HL-60 cells differentiated toward granulocytes by DMSO acquire the ability to adhere to a TSP-substratum and migrate towards TSP, 27, 29 an effect that was related to an increased expression of TSP receptors upon granulocytic differentiation. 41 At least two distinct TSP receptors exist on peripheral neutrophils and neutrophil-like HL-60 cells, reacting with the NH2-terminal heparin-binding domain and the 140 kDa COOH-terminal domain of TSP, respectively. 28, 41 Among possible candidates that could recognize sites on the 140 kDa fragment are CD36, the ␣ V ␤ 3 integrin, a 50 kDa integrinassociated molecule (IAP or CD47) and a 105/80 kDa receptor. 19, 21 Of particular interest, IAP which coassociates with ␤ 3 -like integrins, and possibly other integrins, has been shown to participate in integrin-mediated stimulation of phagocytosis, chemotaxis and oxidative burst in neutrophils as well as the transendothelial migration of these cells. [42] [43] [44] [45] This molecule which consists of an extracellular IgG variable type domain followed by five potentially membrane-spanning hydrophobic helices and a short cytoplasmic tail might be identical to the recently described TSP receptor linked to Gproteins in neutrophils. 28 Antibodies to IAP have been shown to block the integrin-regulated calcium entry in endothelial cells and fibroblasts. 46, 47 Thus, this molecule may provide a signaling pathway by which TSP might modulate cell functions such as chemotaxis, haptotaxis and proliferation.
In summary, this work demonstrates an autocrine role for endogenously secreted TSP in the growth arrest and differentiation of HL-60 cells in response to RA. Thus, TSP as a component of the bone marrow matrix 24 might contribute to the maturation of myeloid cells. The potential modulation of TSP receptors on the surface of HL-60 cells undergoing differentiation as well as delineation of cell signaling pathways are currently under investigation.
